Overview
C-peptide, also known as connecting peptide, is a short chain of amino acids released from pancreatic beta cells during insulin production, as described in the document. It is formed when proinsulin is cleaved into insulin and C-peptide in equal amounts. Unlike insulin, C-peptide is not significantly metabolized by the liver and has a longer half-life in circulation, making it a reliable marker of endogenous insulin secretion.
C-peptide plays an important role in assessing pancreatic beta-cell function and is widely used in the evaluation and management of diabetes mellitus. Because exogenous insulin therapy does not contain C-peptide, measurement of C-peptide helps differentiate between endogenous insulin production and injected insulin. The document highlights that C-peptide also has physiological effects beyond being a marker, including roles in microvascular blood flow, nerve function, and protection against diabetic complications.
Symptoms
C-peptide itself does not directly cause symptoms. Symptoms arise due to underlying conditions associated with abnormal insulin secretion, as outlined in the document.
Low C-peptide levels are commonly associated with insufficient insulin production and may be accompanied by symptoms of hyperglycemia, such as fatigue, weight loss, excessive thirst, and frequent urination. Individuals with very low levels may also experience complications related to poor glycemic control.
High C-peptide levels may be associated with excessive endogenous insulin secretion, which can lead to hypoglycemic symptoms. These may include sweating, palpitations, hunger, confusion, blurred vision, dizziness, and fainting. Symptoms are often episodic and depend on glucose levels at the time of insulin release.
Because symptoms are nonspecific, laboratory measurement of C-peptide is essential for accurate assessment and diagnosis.
Causes
Abnormal C-peptide levels result from conditions affecting insulin production and secretion, as described in the document.
High C-peptide levels may occur due to increased endogenous insulin secretion. Primary causes include insulin-producing tumors such as insulinoma or medication-related stimulation of insulin release. Secondary causes include insulin resistance, obesity, glucose intolerance, and early stages of type 2 diabetes mellitus. Conditions involving excess secretion of insulin-antagonistic hormones, such as Cushing’s syndrome or acromegaly, may also elevate C-peptide levels. Reduced renal clearance due to kidney failure can further increase circulating C-peptide.
Low C-peptide levels are caused by impaired or absent insulin production. This is commonly seen in type 1 diabetes mellitus due to autoimmune destruction of pancreatic beta cells. Other causes include pancreatitis, pancreatic surgery, and autoimmune disorders affecting pancreatic tissue.
Risk Factors
Several factors increase the risk of abnormal C-peptide levels, as outlined in the document.
Risk factors for low C-peptide include type 1 diabetes mellitus, autoimmune pancreatic disease, chronic pancreatitis, and surgical removal of pancreatic tissue. Individuals with long-standing diabetes may also experience declining C-peptide levels due to progressive beta-cell failure.
Risk factors for high C-peptide include insulin resistance, obesity, metabolic syndrome, early type 2 diabetes mellitus, and insulin-secreting tumors. Endocrine disorders that alter hormone balance may further increase insulin secretion and C-peptide levels.
Renal dysfunction is an additional risk factor, as impaired kidney function reduces C-peptide excretion, leading to falsely elevated levels. Medication use and improper timing of sample collection can also affect test results and interpretation.
Prevention
C-peptide abnormalities cannot always be prevented, but early identification and appropriate management of underlying conditions play a crucial role in preventing complications, as emphasized in the document.
Preventive strategies include regular monitoring of pancreatic function in individuals with diabetes or suspected insulin disorders. Timely evaluation helps guide treatment decisions, including insulin therapy and lifestyle modification.
Maintaining a healthy body weight, managing insulin resistance, and achieving good glycemic control reduce stress on pancreatic beta cells and may preserve endogenous insulin secretion. For individuals at risk of hypoglycemia, proper monitoring and medication adjustment help prevent dangerous insulin overproduction.
